Metabiomed Selected for SME Ministry R&D Support Project

Metabiomed is set to accelerate its entry into the biopolymer materials business.

On April 16, Metabiomed announced that it has been selected as the lead research institution for the "Medical New Material Development" project, part of the "SME Technology Innovation Development Project: Global Leading Technology Development (Jump Up)" initiative organized by the Ministry of SMEs and Startups.

Exterior view of Metabiomed headquarters in Heungdeok-gu, Cheongju. Metabiomed

원본보기 아이콘

This project aims to promote innovative growth by supporting R&D (research and development) based on strategic technology development and global technological cooperation, with the goal of expanding the global market presence and strengthening the technological competitiveness of small and medium-sized enterprises.

Through this project, Metabiomed plans to advance its proprietary core technology for synthesizing medical polymer materials and, based on this, secure a materials supply technology platform that spans a full range of high-value-added products in the biohealth sector, from microparticles to implantable devices. By building a technology platform that can be expanded beyond simple material supply to include applied products, the company expects to further strengthen its business competitiveness.

In addition, Metabiomed aims to secure mass production technology for these materials, develop hybrid composite materials that can provide high-load support for orthopedic applications, and complete the localization of high-value-added materials.

Centering on its Materials Innovation Center, which was completed last year, Metabiomed is reorganizing its portfolio around new businesses such as biodegradable polymer materials, polymer fillers, skin boosters, and aesthetic devices, thereby systematically establishing a foundation for mid- to long-term growth.

Previously, in October last year, the company celebrated its 35th anniversary by announcing its "Vision 2030," declaring its commitment to achieving 50 billion won in sales and a corporate value of 1 trillion won by 2030. In particular, biodegradable polymer materials are considered a key material with high applicability in various fields such as sutures and dermal fillers, and are expected to play a significant role in the company's future growth strategy.

This R&D support project will be carried out over approximately two years, from April 2026 to March 2028. The government will provide a total of 1 billion won in funding, and including the company’s own in-kind and cash investments, a total of 1.6 billion won will be invested in research and development.

Jisoo Oh, CEO of Metabiomed, stated, "Through this R&D support project, we plan to further enhance the quality competitiveness of biodegradable polymer materials and establish a foundation for the localization and global market entry of these materials. We will continue to realize sustainable corporate growth and enhance corporate value for our shareholders."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.